"Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine,” CEO Payton Nyquvest said. “The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong US platform through eight established, reputable, efficiently operating and revenue-producing clinics.
#Novamind used in a classroom trial
READ: Numinus Wellness completes first MDMA administration in PTSD trial sponsored by MAPS In a statement, Vancouver- and Toronto-based Numinus said the two companies have a “shared mission” of responsibly reintroducing psychedelic therapy to mental healthcare. The acquisition brings the Numinus network to 13 wellness clinics, four research sites, and one bioanalytical laboratory in North America.
(TSX-V:NUMI, OTC:LKYSF) said it is expanding its presence in the US with the acquisition of Novamind, which owns a network of mental health clinics and research sites, in an all-stock deal worth just over C$26 million.
#Novamind used in a classroom update
The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.Numinus Wellness Inc. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. We are pleased to contribute our clinical expertise and renowned therapy protocols to help achieve this vision." Yaron Conforti, CEO and Director, Novamind, commented: "Bienstar is quickly developing Latin America's first network of mental health clinics specialized in psychedelic medicine. Upon signing a definitive agreement, Bienstar will have access to a broad patient base in Brazil-the largest market in Latin America with 215 million people.
Rasmussen is a pioneer and one of the leading names in psychedelic medicine in Brazil where ketamine and ibogaine are legal for medical use in psychotherapies.
Bruno Rasmussen, Bienstar's Chief Medical Officer, a medical doctor and MAPS-trained therapist with over 27 years of experience. The partnership draws on Novamind's expertise delivering psychedelic-assisted psychotherapy and its successful and replicable model for clinics and clinical research sites in the United States. In December 2021, Novamind announced a strategic investment and advisory agreement with Bienstar.
0 kommentar(er)
